ProPhase Labs, Inc. Proceeds from Sale of Buildings
ProPhase Labs, Inc. (PRPH) reported Proceeds from Sale of Buildings of $2.08 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-31.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfBuildings · last filed 2022-03-31
- ProPhase Labs, Inc. proceeds from sale of buildings for fiscal 2020 was $2.08M.
| Period end | Proceeds from Sale of Buildings 12 month |
|---|---|
| 2020-12-31 | $2.08M 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |